Details of the Drug

General Information of Drug (ID: DMP6IMQ)

Drug Name
Rindopepimut
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 3 [1]
Glioblastoma multiforme 2A00.0 Phase 3 [1]
Cross-matching ID
UNII
K3L4X0501F
DrugBank ID
DB05374
TTD ID
D05FRP

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 5.84E-05 0.32 0.55
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
2 Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.